Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 3114 of 3330
Next
>>
>
77826 to 77850 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
AU565	HER2amp	Luminal	Triciribine	AKT	AKT	0.00213	uM	5901.074	0.9276	0.9213	1.8718
AU565	HER2amp	Luminal	Triciribine	AKT	AKT	0.0107	uM	5901.074	0.6495	0.5882	1.8718
AU565	HER2amp	Luminal	Triciribine	AKT	AKT	0.0533	uM	5901.074	0.3776	0.1887	1.8718
AU565	HER2amp	Luminal	Triciribine	AKT	AKT	0.267	uM	5901.074	0.2380	-0.0710	1.8718
AU565	HER2amp	Luminal	Triciribine	AKT	AKT	1.33	uM	5901.074	0.1351	-0.3137	1.8718
AU565	HER2amp	Luminal	Triciribine	AKT	AKT	6.67	uM	5901.074	0.0532	-0.5829	1.8718
AU565	HER2amp	Luminal	Triciribine	AKT	AKT	33.3	uM	5901.074	0.0075	-0.8539	1.8718
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.0000853	uM	5902.074	0.9690	0.9520	1.2939
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.000427	uM	5902.074	1.0555	1.0853	1.2939
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.00213	uM	5902.074	1.0137	1.0211	1.2939
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.0107	uM	5902.074	0.9832	0.9740	1.2939
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.0533	uM	5902.074	0.9666	0.9481	1.2939
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.267	uM	5902.074	0.8655	0.7888	1.2939
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	1.33	uM	5902.074	0.7526	0.6055	1.2939
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	6.67	uM	5902.074	0.5059	0.1811	1.2939
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	33.3	uM	5902.074	0.2904	-0.2309	1.2939
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.0000853	uM	5903.074	0.9321	0.8731	1.0729
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.000427	uM	5903.074	0.9697	0.9435	1.0729
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.00213	uM	5903.074	0.9883	0.9781	1.0729
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.0107	uM	5903.074	1.0124	1.0232	1.0729
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.0533	uM	5903.074	0.9833	0.9688	1.0729
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	0.267	uM	5903.074	0.8621	0.7416	1.0729
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	1.33	uM	5903.074	0.6833	0.4024	1.0729
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	6.67	uM	5903.074	0.4872	0.0233	1.0729
BT-20	TNBC	Basal A	Triciribine	AKT	AKT	33.3	uM	5903.074	0.2928	-0.3635	1.0729

|<
<<
Previous
Page 3114 of 3330
Next
>>
>
77826 to 77850 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)